• Mission
  • Approach
  • Research
  • About
  • More
    • Mission
    • Approach
    • Research
    • About
  • Mission
  • Approach
  • Research
  • About

CpG Diagnostics

CpG DiagnosticsCpG DiagnosticsCpG Diagnostics

Using cell-free DNA and Machine Learning to detect ovarian cancer earlier

Contact Us

CpG Diagnostics

CpG DiagnosticsCpG DiagnosticsCpG Diagnostics

Using cell-free DNA and Machine Learning to detect ovarian cancer earlier

Contact Us

The Unmet Need in Ovarian Cancer

    

Our mission is to accurately rule in or out ovarian cancer earlier when it's easier to treat and improve the treatment planning of women with ovarian masses.

A New Approach for Ovarian Cancer

We take cell-free DNA found in standard blood samples and apply advanced machine learning models to identify ovarian cancer in early stages.

Learn more

The Diagnostic Gap

While transvaginal ultrasounds and CA-125 blood tests are used in ovarian cancer, there is a lack of reliable screening tests for early stage detection when 5 year survival rates are over 90% vs late stage diagnosis which is 31%. We are using new technology and approaches to disrupt the status quo.

Makers of OvaPrint

Transforming the detection of ovarian cancer

Our flagship blood test detects  the most common and lethal type of ovarian cancer - High Grade Serous Ovarian Cancer (HGSOC) - to help inform the best course of treatment. For any woman with a pelvic mass, we are taking the guessing game out of the detection and treatment process especially for HGSOC which is the most common and most lethal form of ovarian cancer.

Contact Us

Email us for media inquiries, investment opportunities, questions, or if you wish to be enrolled as a clinical site for research.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CpG Diagnostics

Copyright © 2025 CpG Diagnostics - All Rights Reserved.

Powered by